Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B
Chao‐Wei Hsu, Yun‐Fan Liaw(Chang Gung Memorial Hospital), Rong‐Nan Chien(Chang Gung Memorial Hospital), Jia‐Horng Kao(National Taiwan University Hospital), Cheng‐Yuan Peng(China Medical University), Wei‐Wen Su(Taichung Veterans General Hospital), Yi‐Hsiang Huang(First Hospital of Lanzhou University), Heng-Cheng Chu(Tri-Service General Hospital), Chuan-Mo Lee(Kaohsiung Chang Gung Memorial Hospital), Wan‐Long Chuang(Kaohsiung Medical University)
Cited by 26
Related Papers
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
|The Lancet. Gastroenterology & hepatology|2016|2k
Mitotic and G <sub>2</sub> Checkpoint Control: Regulation of 14-3-3 Protein Binding by Phosphorylation of Cdc25C on Serine-216
|Science|1997|1.3k
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update
|Hepatology International|2008|870
SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma
|Journal of Clinical Oncology|2018|653
Hepatitis B Virus Genotype and DNA Level and Hepatocellular Carcinoma: A Prospective Study in Men
|JNCI Journal of the National Cancer Institute|2005|569